Literature DB >> 28871924

Comparison of Doxycycline and Benzathine Penicillin G for the Treatment of Early Syphilis.

Hailu Xiao, Dianchang Liu, Zhen Li, Rongtao Zheng, Zhongwei Li, Jianling Hou, Shengjia Zhang, Tongsheng Chu, Hongqing Tian1, Furen Zhang2.   

Abstract

Doxycycline is the preferred recommended second-line treatment for the treatment of early syphilis. Recent reports showed a declining efficacy trend of doxycycline in treatment of early syphilis. The aim of our study was to assess the serological response to the treatment for early syphilis with doxycycline compared with benzathine penicillin G and evaluate whether doxycycline is still an effective agent for the treatment of early syphilis. A record-based retrospective study was conducted. Patients were diagnosed with early syphilis in an sexually transmitted disease (STD) clinic from January 1, 2008 to December 31, 2014. They were treated with a single dose of benzathine penicillin G 2.4MU or oral doxycycline 100 mg twice daily for 14 days. Pearson's chi-squared test was used for data analysis. 601 cases were included in the final study sample: 105 (17.5%) patients received a 14-day course of doxycycline (doxycycline group), and 496 (82.5%) patients received single-dose benzathine penicillin G (BPG group). The serological responses at 6 months and 12 months after treatment were compared. No statistically significant differences were found between the two groups at 6 months (69.52% vs. 75.00%, P=0.245), and at 12 months (92.38% vs. 96.17%, P=0.115). Doxycycline is still an effective agent for the treatment of early syphilis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28871924

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  2 in total

1.  Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Susan Tuddenham; Khalil G Ghanem
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 9.079

Review 2.  Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review.

Authors:  A S Vickram; Kuldeep Dhama; S Thanigaivel; Sandip Chakraborty; K Anbarasu; Nibedita Dey; Rohini Karunakaran
Journal:  Saudi J Biol Sci       Date:  2022-01-07       Impact factor: 4.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.